Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04195763 · ClinicalTrials.gov registry record
Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa)
A clinical trial, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- 50
- Enrollment target
NCT04195763 is a clinical trial that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 50 participants.
The verdict
NCT04195763 has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
Study Summary
This observational study will evaluate the treatment effect of Strensiq (asfotase alfa) on Patient Reported Outcomes (PROs) in participants diagnosed with pediatric-onset hypophosphatasia (HPP) registered in the patient support program managed by OneSource™.
Interventions
- DRUG asfotase alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2019-11-06 |
| Est. Completion | 2024-04-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04195763
The ClinicalTrials.gov registry entry for NCT04195763 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which asfotase alfa is the first listed.
NCT04195763 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04195763 about?
NCT04195763 is a clinical study titled "Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa)". This observational study will evaluate the treatment effect of Strensiq (asfotase alfa) on Patient Reported Outcomes (PROs) in participants diagnosed with pediatric-onset hypophosphatasia (HPP) registered in the patient support program managed by OneSource™.
What is the current status of trial NCT04195763?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2019-11-06. Estimated completion is 2024-04-12.
What interventions are being tested in trial NCT04195763?
The interventions under investigation include: asfotase alfa (DRUG).
Who is sponsoring clinical trial NCT04195763?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.